Tamarack Advisers, LP Buys Pacira BioSciences Inc, Portola Pharmaceuticals Inc, Nevro Corp, Sells NuVasive Inc, NxStage Medical Inc, Service Corp International

• New Purchases: PCRX, NVRO, ALKS, TMO, CMD,
• Added Positions: PTLA, MDRX, SRCL, ISEE, BIO, HOLX, CORV,
• Reduced Positions: SCI, ATRC, VSI, RIGL, LNTH, OBLN,
• Sold Out: NUVA, NXTM, MCK, OPTN,

For the details of Tamarack Advisers, LP's stock buys and sells, go to https://www.gurufocus.com/guru/tamarack+advisers%2C+lp/current-portfolio/portfolio

1. Allscripts Healthcare Solutions Inc (MDRX) - 3,550,000 shares, 15.43% of the total portfolio. Shares added by 16.39%
2. Stericycle Inc (SRCL) - 510,000 shares, 12.64% of the total portfolio. Shares added by 20.00%
3. Portola Pharmaceuticals Inc (PTLA) - 725,000 shares, 11.46% of the total portfolio. Shares added by 81.25%
4. Lantheus Holdings Inc (LNTH) - 950,000 shares, 10.59% of the total portfolio. Shares reduced by 2.56%
5. Bio-Rad Laboratories Inc (BIO) - 65,000 shares, 9.05% of the total portfolio. Shares added by 8.33%

Tamarack Advisers, LP initiated holding in Pacira BioSciences Inc. The purchase prices were between $36.47 and $43.02, with an estimated average price of $39.13. The stock is now traded at around $46.90. The impact to a portfolio due to this purchase was 5.55%. The holding were 320,000 shares as of .

Tamarack Advisers, LP initiated holding in Nevro Corp. The purchase prices were between $35.52 and $62.62, with an estimated average price of $46.85. The stock is now traded at around $58.03. The impact to a portfolio due to this purchase was 4.56%. The holding were 160,000 shares as of .

Tamarack Advisers, LP initiated holding in Alkermes PLC. The purchase prices were between $28.4 and $36.49, with an estimated average price of $32.98. The stock is now traded at around $25.16. The impact to a portfolio due to this purchase was 2.33%. The holding were 140,000 shares as of .

Tamarack Advisers, LP initiated holding in Thermo Fisher Scientific Inc. The purchase prices were between $212.17 and $273.72, with an estimated average price of $248.4. The stock is now traded at around $261.08. The impact to a portfolio due to this purchase was 1.25%. The holding were 10,000 shares as of .

Tamarack Advisers, LP initiated holding in Cantel Medical Corp. The purchase prices were between $65.31 and $88.63, with an estimated average price of $75.9. The stock is now traded at around $67.04. The impact to a portfolio due to this purchase was 0.91%. The holding were 30,000 shares as of .

Tamarack Advisers, LP added to a holding in Portola Pharmaceuticals Inc by 81.25%. The purchase prices were between $17.93 and $34.72, with an estimated average price of $28.71. The stock is now traded at around $29.66. The impact to a portfolio due to this purchase was 5.14%. The holding were 725,000 shares as of .

Tamarack Advisers, LP added to a holding in IVERIC bio Inc by 200.00%. The purchase prices were between $1.2 and $1.61, with an estimated average price of $1.4. The stock is now traded at around $1.43. The impact to a portfolio due to this purchase was 1.29%. The holding were 3,000,000 shares as of .

Tamarack Advisers, LP sold out a holding in NuVasive Inc. The sale prices were between $44.53 and $58.9, with an estimated average price of $53.1.

Tamarack Advisers, LP sold out a holding in NxStage Medical Inc. The sale prices were between $28.24 and $30, with an estimated average price of $28.95.

Tamarack Advisers, LP sold out a holding in McKesson Corp. The sale prices were between $110.47 and $136.3, with an estimated average price of $123.47.

Tamarack Advisers, LP sold out a holding in OptiNose Inc. The sale prices were between $6.1 and $10.3, with an estimated average price of $7.69.